Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

Fig. 3

Overall survival based on the normalization of duke pancreatic monoclonal antigen type 2 (DUPAN-II) levels during preoperative chemoradiation therapy (CRT) in all 73 patients (A) and 60 patients who underwent resection (B). C Overall survival of patients with normalized and elevated DUPAN-II during preoperative CRT in 73 patients and those with normal pre DUPAN-II levels among all 221 patients with pancreatic cancer

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us